不同质子泵抑制剂对Hp感染胃溃疡的治疗效果及对白细胞介素-33、miR-26a水平的影响

摘要/Abstract

摘要： 目的探讨不同质子泵抑制剂对幽门螺杆菌（Hp）感染胃溃疡的治疗效果及对白细胞介素-33（IL-33）、miR-26a水平影响。方法将2022年6月—2023年6月西安市临潼区人民医院收治的86例Hp感染胃溃疡患者作为研究对象,利用随机数表法分成对照组和观察组,每组43例。给予对照组质子泵抑制剂（奥美拉唑肠溶片）+胶体果胶铋胶囊+克拉霉素片+甲硝唑片四联治疗方案,给予观察组质子泵抑制剂（埃索美拉唑镁）+胶体果胶铋胶囊+克拉霉素片+甲硝唑片四联治疗方案,比较两组临床治疗总有效率、Hp根除率、IL-33水平、miR-26a水平、CD4⁺、CD8⁺、CD4⁺/CD8⁺。结果观察组治疗总疗效高于对照组,差异具有统计学意义（P<0.05）;观察组Hp根除率高于对照组,差异具有统计学意义（P<0.05）。经治疗,两组IL-33水平均明显降低,而miR-26a水平均明显提高,且观察组IL-33水平显著低于对照组,miR-26a水平显著高于对照组（P<0.05）;经治疗,两组CD4⁺、CD8⁺、CD4⁺/CD8⁺水平均明显改善,且观察组CD4⁺水平以及CD4⁺/CD8⁺比值显著高于对照组,CD8⁺水平显著低于对照组（P<0.05）。结论相比于奥美拉唑肠溶片,埃索美拉唑镁可提高患者临床治疗效果和Hp根除率,降低患者IL-33水平、提高miR-26a水平,提高患者免疫功能。

关键词: 质子泵抑制剂, Hp感染, 胃溃疡, 白细胞介素-33, miR-26a

Abstract: Objective To explore the therapeutic effect of different proton pump inhibitors on Helicobacter pylori (Hp) infected gastric ulcers and their impact on interleukin-33 and miR-26a levels. Methods A study was conducted on 86 patients with Hp infected gastric ulcers admitted to the People's Hospital of Lintong District, Xi'an City from June 2022 to June 2023. Divide into two groups using the random number table method, with 43 cases in each group. The control group was given a proton pump inhibitor (omeprazole enteric coated tablets)+colloidal pectin bismuth capsules+clarithromycin tablets+metronidazole tablets quadruple treatment plan, while the observation group was given a proton pump inhibitor (esomeprazole magnesium)+colloidal pectin bismuth capsules+clarithromycin tablets+metronidazole tablets quadruple treatment plan. Compare the total effective rate, Hp eradication rate, the levels of interleukin-33, miR-26a, CD4⁺, CD8⁺, CD4⁺/CD8⁺ between two groups. Results The total therapeutic effect of the observation group was higher than that of the control group, with statistical significance (P<0.05); The Hp eradication rate in the observation group was higher than that of the control group, with statistical significance (P<0.05). After treatment, the levels of IL-33 in both groups were significantly reduced, while the levels of miR-26a were significantly increased. The level of IL-33 s in the observation group was lower than that in the control group, while the level of miR-26a was higher than that in the control group (P<0.05). After treatment, the levels of CD4⁺ and CD8⁺ in both groups showed significant improvement, with the former showing an increase and the latter showing a decrease. The level of CD4⁺ and the ratio of CD4⁺/CD8⁺ in the observation group were higher than those in the control group, while the level of CD8⁺ was lower than those in the control group (P<0.05). Conclusion Compared to omeprazole enteric coated tablets, esomeprazole magnesium can improve clinical treatment efficacy and Hp eradication rate in patients, reduce the level of interleukin-33, increase the level of miR-26a, and improve immune function.

Key words: proton pump inhibitors, Hp infection, gastric ulcer, interleukin-33, MiR-26a

中图分类号:

R573.1

郭兰新, 刘祎昉. 不同质子泵抑制剂对Hp感染胃溃疡的治疗效果及对白细胞介素-33、miR-26a水平的影响[J]. 中华养生保健, 2024, 42(21): 53-56.

GUO Lan-xin, LIU Yi-fang. The Therapeutic Effect of Different Proton Pump Inhibitors on Hp Infected Gastric Ulcers and Their Impact on Interleukin-33 and miR-26a Levels[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(21): 53-56.

参考文献

[1] 聂颖. 自拟清胃疏肝方联合西医常规治疗胃溃疡伴Hp感染的疗效观察及对血清EGF、PGE2水平的影响[J].中国中医药科技,2022,29(6):942-946.
[2] 袁浩壬,付晓林.Hp感染性胃溃疡患者血清炎症因子、MMP-9和TIMP-1水平变化及其与炎性活动度的相关性[J].海南医学,2022,33(8):968-971.
[3] 蔡晓鹤,丁淑婷,叶方益,等.抗幽愈疡汤联合四联疗法治疗Hp相关性胃溃疡的疗效观察[J].中国中医药科技,2022,29(3):438-440.
[4] 陈朝聪,蔡水苗,刘海珊.质子泵抑制剂联合抗生素治疗对Hp阳性慢性萎缩性胃炎患者血清胃泌素SIL-2R CRP水平及免疫功能的影响[J].河北医学,2020,26(3):429-432.
[5] 李彩玲,宋志强,索宝军,等.质子泵抑制剂和阿莫西林双联方案在幽门螺杆菌感染根除治疗中的应用[J].中华医学杂志,2021,101(10):746-749.
[6] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-513.
[7] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:215-216.
[8] 赵静,斯望春,王佩珠,等.幽门螺杆菌阳性胃溃疡患者T淋巴细胞及相关炎症因子水平[J].中华医院感染学杂志,2022,32(7):1014-1017.
[11] 郑秀金,肖佛义,杨卫远.胃得安胶囊联合四联疗法对胃溃疡伴Hp感染患者疗效及血清学指标的影响[J].中国中西医结合消化杂志,2021,29(1):32-35.
[12] 刘婷莉,郭元彪,邓艺,等. Hp感染性胃溃疡患者炎症活动度与血清TNF-α、IL-17表达水平的相关性[J].热带医学杂志,2021,21(9):1154-1157.
[14] 兰春慧. 高剂量质子泵抑制剂-阿莫西林双联方案在幽门螺杆菌根除治疗中的研究进展[J].中国实用内科杂志,2023,43(4):272-276.
[15] 戴书陈,何镔,陆玲玲.何氏胃疡方联合质子泵抑制剂治疗胃溃疡的效果及对炎性因子、胃黏膜屏障功能的影响[J].解放军医药杂志,2022,34(10):89-93,104.
[16] 涂宏飞,张斌,李莉,等.血清IL-32、IL-33、IL-35在不同亚型Hp感染者及胃癌患者中的水平及意义[J].免疫学杂志,2021,37(4):357-362.
[17] 朱秀云,徐晓辉,段磊,等.体检人群幽门螺杆菌感染现状及与糖脂代谢、胃肠激素、miR-26a水平的关联性分析[J].重庆医学,2022,51(3):418-422,427.
[18] 詹士宝,曹正龙.不同质子泵抑制剂四联疗法治疗幽门螺杆菌Hp相关性消化性溃疡的临床疗效比较[J].中国急救复苏与灾害医学杂志,2020,15(z1):59-60,79.
[19] 杨晓茹. 不同质子泵抑制剂联合克拉霉素、阿莫西林治疗消化性溃疡伴Hp感染的效果及安全性对比[J].当代医药论丛,2020,18(17):155-156.
[20] 海花,乌仁图雅,陈金金.“四联”疗法后延长质子泵抑制剂和铋剂治疗对幽门螺杆菌阳性胃溃疡的疗效及安全性分析[J].现代消化及介入诊疗,2020,25(11):1495-1497.

[1]	王晓雯. 5A+5R护理模式结合渐进式饮食管理对消化性胃溃疡患者的影响[J]. 中华养生保健, 2024, 42(7): 81-84.
[2]	宁新平, 周晓萍. VEGF、IL-33、ADA2以及ACE联合检测对胸腔积液性质的诊断价值[J]. 中华养生保健, 2024, 42(20): 189-193.
[3]	木翠翠. 系统护理对改善慢性胃炎及胃溃疡患者的临床疗效、不良心理及生活质量的作用[J]. 中华养生保健, 2024, 42(16): 153-155.
[4]	宋丽凤, 宋丽君. 凝血酶联合质子泵抑制剂治疗上消化道出血的疗效观察[J]. 中华养生保健, 2024, 42(16): 169-171.
[5]	霍岩. 奥美拉唑联合铝碳酸镁对胃溃疡伴出血的治疗效果和安全性分析[J]. 中华养生保健, 2023, 41(3): 41-44.
[6]	庞秀, 马璨, 周俊英, 王乐荣, 王祥生. 胃溃疡的发病机制及与中医脾胃的相关性分析[J]. 中华养生保健, 2023, 41(17): 21-25.
[7]	孔晓静. 胃充盈超声检查诊断胃溃疡的效果分析[J]. 中华养生保健, 2023, 41(13): 185-188.
[8]	刘燕兵, 何晋, 代克行, 申绪牧. 曲美布汀+质子泵抑制剂对胃食管反流病患者肠道菌群影响[J]. 中华养生保健, 2023, 41(1): 152-155.
[9]	朱先艳, 孙秀梅. 正畸治疗对牙周炎患者龈沟液炎性因子水平变化的影响[J]. 中华养生保健, 2022, 40(6): 36-39.
[10]	黄大举. 附子理中汤治疗脾胃虚寒型胃溃疡的临床研究[J]. 中华养生保健, 2022, 40(5): 18-21.
[11]	冯更. 瑞巴派特治疗幽门螺杆菌阳性胃溃疡对血清IL-1,IL-6和MDA指标水平的效果[J]. 中华养生保健, 2022, 40(3): 151-153.
[12]	王越, 王伟明. 清幽益胃汤配合四联疗法对脾胃湿热型Hp感染相关性胃炎患者的疗效[J]. 中华养生保健, 2022, 40(23): 28-31.
[13]	王丹娜. 雷贝拉唑联合血凝酶对老年胃溃疡伴出血的临床分析[J]. 中华养生保健, 2022, 40(12): 76-78.
[14]	张海红. 健康教育联合心理护理对胃溃疡穿孔患者的影响[J]. 中华养生保健, 2022, 40(11): 148-150.
[15]	塔娜. 临床路径式护理在胃溃疡患者中的应用[J]. 中华养生保健, 2022, 40(1): 112-114.